---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-085437"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T03:13:04.398682+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma to merge with Oruka; Oruka holders to own ~97.6% of combined company

## Summary
- Oruka stockholders to own ~97.62% of the combined company; ARCA stockholders ~2.38%.
- Combined company to be renamed Oruka Therapeutics, led by Oruka's CEO.
- PIPE financing of ~$275M from accredited investors to close immediately before the merger.
- Oruka holders (~90%) and ARCA holders (~28.5%) entered support agreements to vote in favor.
- Closing conditions include ARCA stockholder approval, Nasdaq listing, and HSR clearance.

## SEC filing metadata
- accession: 0001193125-24-085437
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/0001193125-24-085437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-085437
- JSON: https://secwatch.observer/filing/0001193125-24-085437.json
- Plain text: https://secwatch.observer/filing/0001193125-24-085437.txt

## Key facts
- Material Agreements
  Oruka Therapeutics, Inc. entered into Agreement and Plan of Merger and Reorganization with ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II LLC, and Oruka Therapeutics, Inc. (effective 2024-04-03).
  - Action: entry
  - Agreement: merger
  - Counterparty: ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II LLC, and Oruka Therapeutics, Inc.
  - Effective: 2024-04-03
  source text: On April 3, 2024, ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), Atlas Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of ARCA (“ Merger Sub I ”), Atlas Merger Sub II LLC, a Delaware limited liability company and a wholly-owned subsidiary of ARCA (“ Merger Sub II ”) and Oruka Therapeutics, Inc., a Delaware corporation (“ Oruka ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/0001193125-24-085437-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.